Regulation of Clinical Research Sponsored by Pharmaceutical Companies
Author Information
Author(s): Julio Sotelo
Primary Institution: National Institute of Neurology and Neurosurgery of Mexico
Hypothesis
A third party must be placed between clinical researchers and drug companies to improve the integrity of clinical trials.
Conclusion
The proposal for a Collegiate Research Council could enhance the reliability of clinical studies and public confidence in drug testing.
Supporting Evidence
- Drug company marketing can distort prescribing patterns.
- The medical profession must base its relationship with drug companies on academic and ethical aims.
- Many trials go unpublished, particularly negative trials.
Takeaway
This study suggests that having a separate group oversee drug research can help make sure that the results are fair and trustworthy.
Methodology
The proposal outlines the creation of a Collegiate Research Council to oversee clinical trials and ensure independence from pharmaceutical companies.
Potential Biases
The current relationship between researchers and drug companies can create bias due to financial incentives.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website